Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CFTR | P13569 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30280732 | 1.00 | LMNA (0.50) | LMNATSHRALDH1A1CFTRHSD17B10 | |
| SCHEMBL3511612 | 0.86 | LMNA (0.59) | LMNATSHRALDH1A1CFTRHSD17B10 | |
| SCHEMBL20146043 | 0.82 | CA1 (0.44) | LMNATSHRALDH1A1CFTRHSD17B10 | |
| SCHEMBL29279663 | 0.82 | TSHR (0.52) | LMNATSHRALDH1A1CFTRHSD17B10 | |
| SCHEMBL29433258 | 0.82 | TSHR (0.61) | LMNATSHRALDH1A1CFTRHSD17B10 | |
| SCHEMBL23659 | 0.82 | TSHR (0.61) | LMNATSHRALDH1A1CFTRHSD17B10 | |
| SCHEMBL265052 | 0.81 | TSHR (0.63) | TSHRALDH1A1HSD17B10CA1CA2 | |
| SCHEMBL30906644 | 0.81 | NPC1 (0.40) | LMNATSHRALDH1A1HSD17B10SLC6A3 | |
| SCHEMBL27208786 | 0.81 | NPC1 (0.40) | LMNATSHRALDH1A1HSD17B10SLC6A3 | |
| SCHEMBL1962462 | 0.81 | CA1 (0.53) | LMNATSHRALDH1A1CFTRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 522 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692101-B1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTR S R L (IT) | 2022-01-12 | — | — | EP | claimed |
| EP-3692101-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | Alfa Instruments S.r.l. (IT) | 2020-08-12 | — | — | EP | claimed |
| WO-2019068935-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTRUMENTS S.R.L. (IT) | 2019-04-11 | — | — | WO | claimed |
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122010947-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12617796-B2 | Antagonists of the adenosine A2a receptor | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SHANGHAITECH UNIVERSITY (CN) | 2026-03-24 | — | — | US | disclosed |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | NEWAVE PHARMACEUTICAL INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4703358-A1 | BENZO SIX-MEMBERED HETEROCYCLIC GSPT1 PROTEIN DEGRADATION AGENT AND USE THEREOF | China Pharmaceutical University (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | disclosed |
| US-6518257-B1 | 1-substituted phenyl-1-(1h-imidazol-4-yl) alcohols, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1227086-A1 | 1-SUBSTITUTED PHENYL-1-(1H-IMIDAZOL-4-YL) ALCOHOLS, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-07-31 | — | — | EP | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-5387582-A | Immunomodulators; useful in treatment and prophylaxis of diabetes, hypertension, rheumatoid arthritis and asthma | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESEL SKAB) (DK) | 1995-02-07 | — | — | US | disclosed |
| WO-1995003300-A1 | HETEROARYL QUINOLINES AS INHIBITORS OF LEUKOTRIENE BIOSYNTHESIS | MERCK FROSST CANADA INC. (CA) | 1995-02-02 | — | — | WO | disclosed |
| EP-0506794-A1 | NOVEL VITAMIN D ANALOGUES. | LEO PHARM PROD LTD (DK) | 1992-10-07 | — | — | EP | disclosed |
| WO-1991009841-A1 | NOVEL VITAMIN D ANALOGUES | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab) (DK) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582641-B2 | Sulfur-containing compound based on glutarimide skeleton and application thereof | SUCNR1, SRD5A1, GLS | LMNA 1605/4885TSHR 1830/4885ALDH1A1 697/4885 |
| US-12617796-B2 | Antagonists of the adenosine A2a receptor | ADORA2A, ADORA2B, ADORA3 | LMNA 3604/4885TSHR 81/4885ALDH1A1 1348/4885 |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | LMNA 3635/4885TSHR 1322/4885ALDH1A1 2514/4885 |
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | PSMB2, PSME3, PSMB3 | LMNA 2661/4885TSHR 2192/4885ALDH1A1 4614/4885 |
| US-12569564-B2 | Spirocyclic MDM2 modulator and uses thereof | MDM2, TP53, XIAP | LMNA 1263/4885TSHR 1018/4885ALDH1A1 1320/4885 |
| US-12583862-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, PSMB2, PSME3 | LMNA 2427/4885TSHR 3211/4885ALDH1A1 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.